Verify regulatory 503A compliance and calculate out-of-pocket savings for compounded Tirzepatide & Semaglutide in Delaware compared to retail commercial list prices ($1250/mo).
Status: DE Admin Code Title 24 Section 2500
Delaware permits licensed telehealth medical providers to prescribe verified compounded GLP-1 medications through certified 503A pharmacies.
Statutory Citation: DE Board of Pharmacy Compounding Standards
Delaware permits licensed telehealth medical providers to prescribe verified compounded GLP-1 medications through certified 503A pharmacies.
Yes, under FDA 503A statutory guidance and Delaware Board of Pharmacy rules, certified compounding pharmacies may dispense patient-specific formulations.
Average cash-pay clinical telehealth subscriptions in Delaware average $295/month, compared to $1,250/month for retail commercial brands.
Yes. Delaware permits synchronous telehealth physician evaluations and direct refrigerated shipping from licensed 503A facilities.
Explore statutory rules, state benchmarks, and customized calculation models across all 51 jurisdictions.
Browse deep clinical analysis and metabolic decision models on Groundwork.